-   Utilizing Ascletis' Peptide Oral Transport ENhancement Technology (POTENT), ASC36 oral tablets achieved absolute oral bioavailability of 6% to 8% at steady state, in non-human primate (NHP) studies. -   In NHPs, ASC36 oral tablets reduced mean body weight up to... The post Ascletis Selects Oral Amylin Receptor Peptide Agonist, ASC36, for Clinical Development appeared first on Kosmo Digital .